循证预防——阿尔茨海默病

2020-09-08 Journal of Neurology, Neurosurgery & Psychiatry 20 July 2020. doi: 10.1136/jnnp-2019-321913

痴呆症的患病率和发病率有明确的下降趋势。过去几十年来,科学家努力更新有关如何预防阿尔茨海默氏病(AD)的证据。由于不同的研究设计具有不同的目标和可信度,因此难以解释预防阿尔茨海默病(AD)的依据。作者

中文标题:

循证预防——阿尔茨海默病

发布机构:

发布日期:

2020-09-08

简要介绍:

痴呆症的患病率和发病率有明确的下降趋势。过去几十年来,科学家努力更新有关如何预防阿尔茨海默氏病(AD)的证据。由于不同的研究设计具有不同的目标和可信度,因此难以解释预防阿尔茨海默病(AD)的依据。作者用前瞻性研究完成了对当前病例的系统评价和Meta分析。

方法:从开始到2019年3月1日,搜索电子数据库和相关网站。包括观察性前瞻性研究(OPS)和随机对照试验(RCT)。 纳入标准如下:(1)OPS研究根据国家神经病学及中风研究所和阿尔茨海默病及相关疾病协会(NINCDS-ADRDA) 标准(2)英文撰写的出版物,可轻松获取所有包含的文章的源信息。详细的排除标准如图1所示。Cochrane工具或NOS的总分被认为是评估每项研究总体偏倚风险的指标。 每个项目的得分均评估了相关的偏见风险。 然后,根据三个领域的得分组合,将每个Meta分析结果的可信度分为四个等级:好(G级),可接受(A±等级),易感(S±等级)和差(P等级)。没有患者参与设定研究问题或结果测量,也没有参与制定研究设计或实施计划。 没有患者被要求就结果的解释或撰写提出建议。 没有计划将研究结果传播给研究参与者或相关患者社区。对于RCT,进行了涵盖11种干预措施的29项Meta分析,

结果:

列出了二十一个具有不同证据水平的基于证据的建议(A级为11个,B级为10个)和建议强度(I级为19个,III级为两个)。 19个因素,包括10个具有A级证据的因素(认知活动,高同型半胱氨酸血症,晚期BMI升高,抑郁症,压力,糖尿病,头部创伤,中年高血压,体位性低血压和教育)和9个具有B级证据的因素(肥胖 , 体育锻炼,吸烟,睡眠,CVD,体弱,房颤和维生素C)提出了二十一种基于临床证据的建议,为临床医生和患者提供了预防AD的基于循证的指南。 这些建议有可靠但不确定的证据,包括糖尿病,高同型半胱氨酸血症,BMI管理不佳,教育程度降低,中年高血压,体位性低血压,头部外伤,认知活动减少,压力和抑郁。研究表明迫切需要更多高质量的OPS和RCT,以加强证据基础,以发现更多有希望的预防AD的方法。

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=789681c0019e118f, title=循证预防——阿尔茨海默病, enTitle=, guiderFrom=Journal of Neurology, Neurosurgery & Psychiatry 20 July 2020. doi: 10.1136/jnnp-2019-321913, authorId=0, author=, summary=痴呆症的患病率和发病率有明确的下降趋势。过去几十年来,科学家努力更新有关如何预防阿尔茨海默氏病(AD)的证据。由于不同的研究设计具有不同的目标和可信度,因此难以解释预防阿尔茨海默病(AD)的依据。作者, cover=, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue Sep 08 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p style="color: #232323;">痴呆症的患病率和发病率有明确的下降趋势。过去几十年来,科学家努力更新有关如何<a style="color: #2f92ee;" href="https://www.medsci.cn/guideline/list.do?q=%E9%A2%84%E9%98%B2">预防</a>阿尔茨海默氏病(AD)的证据。由于不同的研究设计具有不同的目标和可信度,因此难以解释预防阿尔茨海默病(AD)的依据。作者用前瞻性研究完成了对当前病例的系统评价和Meta分析。</p> <p style="color: #232323;">方法:从开始到2019年3月1日,搜索电子数据库和相关网站。包括观察性前瞻性研究(OPS)和随机对照试验(RCT)。 纳入标准如下:(1)OPS研究根据国家神经病学及中风研究所和阿尔茨海默病及相关疾病协会(NINCDS-ADRDA) 标准(2)英文撰写的出版物,可轻松获取所有包含的文章的源信息。详细的排除标准如图1所示。Cochrane工具或NOS的总分被认为是评估每项研究总体偏倚风险的指标。 每个项目的得分均评估了相关的偏见风险。 然后,根据三个领域的得分组合,将每个Meta分析结果的可信度分为四个等级:好(G级),可接受(A&plusmn;等级),易感(S&plusmn;等级)和差(P等级)。没有患者参与设定研究问题或结果测量,也没有参与制定研究设计或实施计划。 没有患者被要求就结果的解释或撰写提出建议。 没有计划将研究结果传播给研究参与者或相关患者社区。对于RCT,进行了涵盖11种干预措施的29项Meta分析,</p> <p style="color: #232323;"><img class="wscnph" src="https://img.medsci.cn/2020912/1599926149021_2026338.gif" /></p> <p style="color: #232323;">结果:</p> <p style="color: #232323;">列出了二十一个具有不同证据水平的基于证据的建议(A级为11个,B级为10个)和建议强度(I级为19个,III级为两个)。 19个因素,包括10个具有A级证据的因素(认知活动,高同型半胱氨酸血症,晚期BMI升高,抑郁症,压力,糖尿病,头部创伤,中年高血压,体位性低血压和教育)和9个具有B级证据的因素(肥胖 , 体育锻炼,吸烟,睡眠,CVD,体弱,房颤和维生素C)提出了二十一种基于临床证据的建议,为临床医生和患者提供了预防AD的基于循证的指南。 这些建议有可靠但不确定的证据,包括<a style="color: #2f92ee;" href="https://www.medsci.cn/search?q=%E7%B3%96%E5%B0%BF%E7%97%85">糖尿病</a>,高同型半胱氨酸血症,BMI<a style="color: #2f92ee;" href="https://www.medsci.cn/guideline/list.do?q=%E7%AE%A1%E7%90%86">管理</a>不佳,教育程度降低,中年高血压,体位性低血压,头部外伤,认知活动减少,压力和抑郁。研究表明迫切需要更多高质量的OPS和RCT,以加强证据基础,以发现更多有希望的预防AD的方法。</p>, tagList=[TagDto(tagId=2344, tagName=阿尔茨海默氏病)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其它, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5872, appHits=491, showAppHits=0, pcHits=903, showPcHits=5380, likes=5, shares=27, comments=17, approvalStatus=1, publishedTime=Sun Sep 13 19:57:46 CST 2020, publishedTimeString=2020-09-08, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Sun Sep 13 19:57:01 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 21:03:04 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击:
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1073307, encodeId=a43d10e330737, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211123/64c41737003e416fb231f175c9883555/93379e00f5544edebd52e0a2f4277793.jpg, createdBy=9e575730125, createdName=ms2000001465289483, createdTime=Tue Nov 23 21:18:51 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006087, encodeId=caff100608e3d, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/be26aeafbef442f090be3dcf7bac09eb/952d74a976ef42309ef717796ab54aa1.jpg, createdBy=9e395567281, createdName=刀刀4492, createdTime=Sun Aug 08 18:23:16 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996408, encodeId=9e9e9964085c, content=厉害了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Mon Jul 05 14:03:20 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974317, encodeId=5f8e9e4317cf, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:11 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974316, encodeId=6fa39e431601, content=bic, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:07 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-11-23 ms2000001465289483

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1073307, encodeId=a43d10e330737, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211123/64c41737003e416fb231f175c9883555/93379e00f5544edebd52e0a2f4277793.jpg, createdBy=9e575730125, createdName=ms2000001465289483, createdTime=Tue Nov 23 21:18:51 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006087, encodeId=caff100608e3d, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/be26aeafbef442f090be3dcf7bac09eb/952d74a976ef42309ef717796ab54aa1.jpg, createdBy=9e395567281, createdName=刀刀4492, createdTime=Sun Aug 08 18:23:16 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996408, encodeId=9e9e9964085c, content=厉害了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Mon Jul 05 14:03:20 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974317, encodeId=5f8e9e4317cf, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:11 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974316, encodeId=6fa39e431601, content=bic, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:07 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-08-08 刀刀4492

    学习一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1073307, encodeId=a43d10e330737, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211123/64c41737003e416fb231f175c9883555/93379e00f5544edebd52e0a2f4277793.jpg, createdBy=9e575730125, createdName=ms2000001465289483, createdTime=Tue Nov 23 21:18:51 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006087, encodeId=caff100608e3d, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/be26aeafbef442f090be3dcf7bac09eb/952d74a976ef42309ef717796ab54aa1.jpg, createdBy=9e395567281, createdName=刀刀4492, createdTime=Sun Aug 08 18:23:16 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996408, encodeId=9e9e9964085c, content=厉害了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Mon Jul 05 14:03:20 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974317, encodeId=5f8e9e4317cf, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:11 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974316, encodeId=6fa39e431601, content=bic, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:07 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-07-05 李曌

    厉害了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1073307, encodeId=a43d10e330737, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211123/64c41737003e416fb231f175c9883555/93379e00f5544edebd52e0a2f4277793.jpg, createdBy=9e575730125, createdName=ms2000001465289483, createdTime=Tue Nov 23 21:18:51 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006087, encodeId=caff100608e3d, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/be26aeafbef442f090be3dcf7bac09eb/952d74a976ef42309ef717796ab54aa1.jpg, createdBy=9e395567281, createdName=刀刀4492, createdTime=Sun Aug 08 18:23:16 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996408, encodeId=9e9e9964085c, content=厉害了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Mon Jul 05 14:03:20 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974317, encodeId=5f8e9e4317cf, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:11 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974316, encodeId=6fa39e431601, content=bic, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:07 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-06-17 ms6000000626606872

    不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1073307, encodeId=a43d10e330737, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211123/64c41737003e416fb231f175c9883555/93379e00f5544edebd52e0a2f4277793.jpg, createdBy=9e575730125, createdName=ms2000001465289483, createdTime=Tue Nov 23 21:18:51 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006087, encodeId=caff100608e3d, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/be26aeafbef442f090be3dcf7bac09eb/952d74a976ef42309ef717796ab54aa1.jpg, createdBy=9e395567281, createdName=刀刀4492, createdTime=Sun Aug 08 18:23:16 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996408, encodeId=9e9e9964085c, content=厉害了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Mon Jul 05 14:03:20 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974317, encodeId=5f8e9e4317cf, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:11 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974316, encodeId=6fa39e431601, content=bic, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/1d69e2408632403e8b72c6b977541846/ca7d5d2fa11e4af9994bfb17cf8fa279.jpg, createdBy=687f5441741, createdName=ms6000000626606872, createdTime=Thu Jun 17 10:02:07 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-06-17 ms6000000626606872

    bic

    0